Article 168 of the Treaty on the Functioning of the European Union requires the EU to ensure that a high level of human health protection is part of all its policies. The European Union is to work with the Member States to improve public health, prevent human illness and eliminate sources of danger to physical and mental health.
To this end the European Commission put forward a new approach for EU health policy for the period 2008-13 in its White Paper Together for Health: A Strategic Approach for the EU 2008-13 (COM(2007) 630 final). This strategy provides an overarching framework which covers not only core European health issues but also broader aspects such as health in all policies and global health.
The second programme of Community action in the field of health (2008-13) (hereinafter referred to as the ‘Health Programme’ or ‘Programme’) supports the implementation of this strategy. It is based on Decision No 1350/2007/EC (hereinafter referred to as the ‘Programme Decision’).
The mission of the Health Programme is to complement, support and add value to the policies of the Member States. Is also seeks to contribute to increased solidarity and prosperity in the European Union by protecting and promoting human health and safety and by improving public health. The Programme pursues the following objectives, as set in article 2.2 of the Programme Decision:
improving citizens’ health security;
promoting health, including the reduction of health inequalities;
generating and disseminating health information and knowledge.
In Article 8(1) of the Programme Decision it is stated that the Commission shall adopt:
the annual Work Plan for the implementation of the Programme, setting out:
priorities and actions to be undertaken, including the allocation of financial resources;
criteria for the percentage of Community financial contribution, including criteria for assessing whether or not exceptional utility applies;
the arrangements for implementing the joint strategies and actions referred to in Article 9;
selection, award and other criteria for financial contributions to the actions of the Programme in accordance with Article 4.
According to Article 75 of the Financial Regulation (FR) applicable to the general budget of the European Communities, the commitment of the expenditure should be preceded by a financing decision adopted by the institution or the authorities to which powers have been delegated by the institution. According to Article 90 of the detailed rules for the implementation of the Financial Regulation (IR), the decision adopting the annual work programme referred to in Article 110 of the FR, may be considered to be the financing decision provided that this constitutes a sufficiently detailed framework. This document aims to fulfil those obligations and present the different activities scheduled for 2011 which is the fourth year of the implementation of the Health Programme.
In addition to the Member States of the European Union, the Health Programme is open for the participation of third countries. EFTA/EEA countries Island, Liechtenstein and Norway participate in the Programme in accordance with the conditions established in the EEA agreement. Other third countries, in particular European neighbourhood policy countries, countries that are applying for, are candidates for, or are acceding to membership of the EU as well as the western Balkan countries included in the stabilisation and association process may participate in the Programme provided that the necessary agreements are in place. Out of these third countries Croatia has concluded these arrangements and participates in the Programme.
The Programme Decision sets a total budget of EUR 321500000 for the period 1 January 2008-31 December 2013. The budgetary authority has approved a total budget of EUR 48460000 [indicative amount, subject to the final adoption of the budget by the Budgetary Authorities] for 2011 for budget lines 17 03 06 and 17 01 04 02:
EUR 47060000 for 17 03 06 — EU action in the field of health (operating budget),
EUR 1400000 for 17 01 04 02 — Expenditure on administrative management (administrative budget).
Additional contributions from the EFTA/EEA countries and Croatia are estimated at EUR 1153348 from EFTA/EEA and EUR 138000 from Croatia.
This brings up the total for budget line 17 03 06 to EUR 48313028 and the total for budget line 17 01 04 02 to EUR 1438320.
The amounts given in the following chapters are indicative. In accordance with Article 90(4) of IR, non-substantial variations in the order of +/– 20 % of each item are possible under each financing mechanism.
The budget line 17 01 04 02 — Expenditure on administrative management will be used to finance activities such as organisation of conferences, expert meetings and workshops, including seminars organised at national level among groups of experts to exchange best practices in the areas covered by this work plan. This budget line will also be used to cover publications and communication initiatives.
The Executive Agency for Health and Consumers (EAHC) assists the Commission in the implementation of this work plan according to Commission Decision C(2008) 4943 of 9 September 2008. The budget line for administrative appropriations related to EAHC is 17 01 04 30.
The available appropriations under budget line 17 03 06 — EU action in the field of health will be used to award project grants, operating grants, grants for joint actions, conference grants and direct grants to international organisations as well as to cover procurement and other actions. All grants are covered by written agreement.
In accordance with recital 33 of the Programme Decision, collaboration with third countries not participating in the programme should be facilitated. However, these countries cannot receive any financial contributions under the Health Programme. Nevertheless, travel and subsistence expenses for experts invited from or travelling to such countries can be considered eligible costs in duly justified, exceptional cases, where this directly contributes to the objectives of the Programme.
The total indicative amount for project grants is estimated at EUR 4650000. They are calculated on the basis of eligible costs incurred. The maximum rate for EU co-financing is 60 %. However, this may go up to 80 % in case a proposal meets the criteria for exceptional utility. Annex II contains the exclusion, eligibility, selection and award criteria for project grants. Annex VII contains the criteria for exceptional utility.
Only proposals which directly correspond to the topic and description as set out in this work plan and where ‘project grant’ is indicated as the financing mechanism will be considered for funding. Proposals which only address the wider subject area without matching the specific description of a given action will not be considered for funding. For each of the actions, only one proposal will be funded, except where it is mentioned otherwise.
The indicative timetable for publishing the call for proposals for project grants in the Official Journal is the first quarter of 2011.
The total indicative amount for operating grants is estimated at EUR 4000000. They are calculated on the basis of eligible costs incurred. The maximum rate for EU co-financing is 60 %. However, this may go up to 80 % in case a proposal meets the criteria for exceptional utility.
Operating grants may be awarded to the renewal of operating grants awarded to non-governmental bodies and specialised networks under the work plan for 2010. New operating grants may be awarded to non-governmental bodies and specialised networks active in areas corresponding to the priorities of the Health Programme and to the priorities of this work plan as set out below in point 3 Priorities for 2011.
As laid down in Article 4(2) of the Programme Decision, the renewal of financial contributions set out in paragraph 1(b) to non-governmental bodies and specialised networks may be exempted from the principle of gradual decrease. As a general rule, this exemption will apply to applicant organisations not receiving any of their funding from the private sector [The term ‘private sector’ covers ‘for-profit’ companies/enterprises/corporations, business organisations or other entities irrespective of their legal nature (registered/not registered), ownership (wholly or partially privately owned/state owned) or size (large/small), if they are not controlled by the public.] or other conflicting interest for their functioning (core funding). For all other renewed operating grants, a decrease of 5 percentage points as compared to the Community co-financing percentage agreed in the grant agreement following the call for proposals 2010 will be applied. In any case, the amount of EU co-funding cannot be higher than the amount granted in 2010. Annex III contains the exclusion, eligibility, selection and award criteria for operating grants. Annex VII contains the criteria for exceptional utility.
The indicative timetable for publishing the call for proposals for operating grants in the Official Journal is the first quarter of 2011.
The total indicative amount for joint actions is estimated at EUR 17040000. Joint actions enable the competent authorities of the Member States/other countries participating in the Health Programme and the European Commission to take forward work on jointly identified issues. Public bodies or non-governmental bodies based in a Member State or in other participating country which participates in a given joint action may participate in the joint action. However, they have to be expressly mandated to do so by the authorities of the Member State/other participating country concerned.
Grants for joint actions are calculated on the basis of eligible costs incurred. The maximum rate of EU co-financing is 50 %. However, this may go up to 70 % in cases of exceptional utility. The five joint actions proposed in this work plan significantly contribute to the objectives of the Europe 2020 Strategy set out in Commission Communication COM(2010) 2020 of 3 March 2010 on Europe 2020 — A strategy for smart, sustainable and inclusive growth. Therefore they are considered of exceptional utility. Four of these will be awarded co-funding of 60 % and one of 70 %. These joint actions are:
support to the implementation of national plans/strategies on rare diseases and related measures to implement Council Recommendation and Commission Communication on rare diseases; maximum EU co-funding EUR 3000000, co-funding percentage 60 %,
cross-border eHealth instruments as supporting tools for medical information and research; maximum EU co-funding EUR 2400000, co-funding percentage 60 %,
complementary joint action on pilot HTA’s on targeted health technologies; maximum EU co-funding EUR 6600000, co-funding percentage 70 %,
patient safety and quality of healthcare; maximum EU co-funding EUR 3600000, co-funding percentage 60 %,
assisting Member States in reaching the full potential of deceased and living donation; maximum EU co-funding EUR 1440000, co-funding percentage 60 %.
Annex IV contains the exclusion, eligibility, selection, and award criteria for joint actions.
Member States/other countries participating in the Health Programme which wish to participate in joint actions must declare this intention to the Commission. With the exception of NGOs operating at EU level, only organisations established in Member States/other countries participating in the Health Programme which have made this declaration can apply for participation in joint actions. The Commission, assisted by EAHC, will offer help to participating Member States/other countries participating in the Health Programme to ensure a transparent procedure to designate national NGOs to participate in joint actions.
The indicative timetable for publishing the call for proposals for joint actions in the Official Journal is the first quarter of 2011.
The total indicative amount for conferences is EUR 800000: EUR 200000 for Presidency conferences, and EUR 600000 for other conferences. For administrative reasons, conferences eligible for co-funding, apart from Presidency conferences, must take place in 2012.
According to article 168(1) point (c) of the IR, grants can be allocated without a call for proposals to organisations in a de jure or de facto monopoly situation, duly substantiated in the award decision.
Presidency conferences which are highly political in nature and which involve representation at the highest level both from National Authorities and European representatives are to be organised exclusively by the Member State holding the Presidency of the EU. Given the unique role of the Presidency in the framework of EU activities, the Member State responsible for the organisation of the event is considered as having a de jure monopoly.
Two conferences organised by the Presidencies of the European Union, one for the Presidency in the second half of 2011 and the other for the Presidency in the first half of 2012, may receive up to EUR 100000 each. The maximum rate of EU co-financing is 50 % of eligible costs incurred.
The Presidency shall submit a request for a grant to EAHC, via the Permanent Representation, for the conference concerned at least 4 months before the event. The request for a grant shall specify the topic of the conference, the draft programme, the provisional budget and the composition of the scientific and organisational committees.
The Presidency conferences to be financed under this work plan are: ‘European Brain Policy Forum; Ageing, Stroke and Alzheimer — finding innovative solutions’ to be held in November 2011 under the Polish Presidency, and a conference to be held in the first half of 2012 under the Danish Presidency which will be the object of a separate financing Decision once the details become known.
Conference grants may be awarded to the organisation of conferences which directly correspond to the priorities of the Health Programme and to the priorities of this work plan as set out below in point 3 Priorities for 2011 and which have a wide European dimension. They have to be organised by a public or non-profit making body which is established in a country participating in the Health Programme and which has relevant experience of cooperation at EU level. Conferences may receive up to EUR 100000 (maximum 50 % of the total budget). Annex V contains the exclusion, eligibility, selection and award criteria for conferences other than Presidency conferences.
The indicative timetable for publishing the call for proposals for conferences in the Official Journal is the first quarter of 2011.
The total indicative amount for direct grants is estimated at EUR 3200000. These will be based on effective collaboration with the Commission.
For this work plan, an international organisation is defined as a form of intergovernmental cooperation established by states through the signature of an international agreement that is registered or submitted to be registered at the Secretariat of the United Nations, has a permanent organisational structure and is endowed with a legal status based on the relevant international agreement that enables the exercise of its functions and the fulfilment of its purpose.
According to Article 168(1) point (f) of the IR, funding for actions with international organisations will be allocated through grant agreements without a call for proposals on topics specifically identified in this work plan. International organisations and their national or regional offices are not eligible for funding as main or associated beneficiaries under any calls for proposals. The maximum rate for EU co-financing is 60 % of the eligible costs effectively incurred. In accordance with recital 33 of the Programme Decision, activities involving third countries not participating in the Health Programme shall not be considered eligible costs. However, travel and subsistence expenses for experts invited from or travelling to such countries can be considered eligible costs in duly justified, exceptional cases, where this directly contributes to the objectives of the Health Programme.
Funding can only be awarded to the following international organisations in 2011:
Council of Europe (CoE),
European Observatory on Health Policies and Health Systems,
International Agency for Research on Cancer (IARC),
Organisation for Economic Cooperation and Development (OECD),
World Health Organisation (WHO).
The total indicative amount for procurement is estimated at EUR 17753028.
Calls for tenders are envisaged to be published in the first semester of 2011 in the Official Journal. Framework contracts and new service contracts will be used as indicated in this work plan.
The total indicative amount for other actions is estimated at EUR 870000.
These cover contributions paid by the EU as subscriptions to bodies of which they are members in the meaning of Article 108(2) point (d) of the FR, and an administrative agreement with the Joint Research Centre (JRC) and special indemnities paid to experts for their participation in meetings and work on scientific opinions in accordance with Commission Decision 2008/721/EC [OJ L 241, 10.9.2008, p. 21.]: special indemnities.
In its Communication COM(2010) 2020, the European Commission presents a strategy for reinvigorating Europe in the next 10 years. Actions presented in this work plan are based in particular on two of the priorities of that strategy: Smart growth and Inclusive growth. They seek to address, among others, the challenge of promoting an active and healthy ageing population, and reducing health inequalities.
The Smart Growth priority builds on knowledge and innovation. Its flagship initiative Innovation Union seeks to focus policies to address the demographic change in the EU post the baby-boom generation. By 2050 the number of people over 50 will rise by 35 % and that over 85 will triple. This will place an increasing strain on health systems. In the European Innovation Partnership in the field of active and healthy ageing set out in Commission Communication COM(2010) 546 final of 6 October 2010 on Europe 2020 Flagship Initiative Innovation Union the Commission calls for measures to prevent and address diseases which affect older people with a particular focus on chronic and rare diseases. This work plan seeks to do so by addressing factors such as nutrition, tobacco and alcohol which underlie many of these age-related chronic diseases, and by taking work forward on cancer and rare diseases. EU cooperation on health technology assessment supports this objective. The work plan also supports work on the safety of blood, tissues, cells and organs which contributes to improving health across the lifecycle thereby contributing to healthy ageing.
Another Smart Growth flagship initiative, A Digital Agenda for Europe, seeks to deliver economic and social benefits from a Digital Single Market. This work plan contributes to this objective by supporting measures that apply information and communication technologies in the area of health.
The goal of the Inclusive growth priority of the Europe 2020 Strategy is a high employment economy which delivers economic, social and territorial cohesion. Ensuring a healthy workforce with less absenteeism can contribute to Europe’s productivity. This work plan further aims to contribute to growth through action aimed at bridging health inequalities to ensure better health for all and better access to health care systems. In turn, this improves citizens’ capacity to contribute to society and reduces poverty and social exclusion, thus contributing to the Flagship Initiative against poverty.
The work plan for 2011 focuses on five main areas. These are: Health Information and advice; Diseases; Health determinants; Health systems; and Legislation on products and substances.
The work plan supports generating the data and scientific opinions that health stakeholders from policy makers to individuals need to be able to make informed decisions. However, generating the information is not enough. In order for it to be effective, it must reach its targets. This requires setting up efficient and user-friendly dissemination channels. These include in particular the setting up and running a knowledge management system.
Work on diseases in the 2011 work plan focuses on cancer and rare diseases. Cancer is the second biggest cause of death of men and women. The aim of the Commission as set out in Commission Communication COM(2009) 291 final of 24 June 2009 on Action Against Cancer: European partnership is to reduce cancer incidence by 15 % by 2020. This work plan supports activities that are designed to help reach that goal. EU action on rare diseases pools fragmented resources across the Member States. This contributes to improved diagnostics and treatment. Commission Communication COM(2008) 679 final of 11 November 2008 on Rare diseases: Europe’s challenges and Council Recommendation 2009/C 151/02 of 8 June 2009 on an action in the field of rare diseases [OJ C 151, 3.7.2009, p. 7.] set the framework for activities supported by this work plan. Pandemic preparedness has become evermore important in the wake of recent avian flu and H1N1 crises. Work supported by this work plan focuses on applying lessons learnt from the H1N1 pandemic. This work plan also finances work on prevention strategies for HIV and co-infections.
Many of today’s debilitating diseases, such as cancer and diabetes, have a direct link to what and how people eat and drink and what kind of lifestyles they have. Work on health determinants is essential in promoting health and thereby preventing disease, thus contributing to active and healthy ageing. This work plan supports activities on a number of key health determinants: social determinants and health inequalities; nutrition and physical activity; and alcohol and tobacco.
Action under this heading aims at ensuring high-quality, safe and efficient cross-border healthcare. The use of new technology has a key role in making cross-border health care a success. This work plan supports work on patient safety, health technologies and their assessment as well as on health work force.
Activities with regard to the quality and safety of human substances support the implementation of Commission Communication COM(2008) 819 final of 8 December 2008 on an Action Plan on Organ Donation and Transplantation (2009 to 2015): Strengthened Cooperation between Member States and Directive 2002/98/EC of the European Parliament and of the Council of 27 January 2003 setting standards of quality and safety for the collection, testing, processing, storage and distribution of human blood and blood components and amending Directive 2001/83/EC [OJ L 33, 8.2.2003, p. 30.]. The other two areas where this work plan finances work related to EU legislation is tobacco and medicinal products.